Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
Express Scripts
Cantor Fitzgerald
Colorcon
Moodys
QuintilesIMS
McKinsey
Dow
Healthtrust

Generated: October 20, 2018

DrugPatentWatch Database Preview

Epoprostenol sodium - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for epoprostenol sodium and what is the scope of epoprostenol sodium freedom to operate?

Epoprostenol sodium is the generic ingredient in three branded drugs marketed by Teva Pharms Usa, Glaxosmithkline Llc, and Actelion Pharms Ltd, and is included in three NDAs. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.

There are seven drug master file entries for epoprostenol sodium. Three suppliers are listed for this compound.

Pharmacology for epoprostenol sodium
Ingredient-typeProstaglandins I
Drug ClassProstacycline Vasodilator
Physiological EffectVasodilation
Medical Subject Heading (MeSH) Categories for epoprostenol sodium
Synonyms for epoprostenol sodium
(5E)-5-[(3aR,4R,5R,6aS)-5-hydroxy-4-[(E,3R)-3-hydroxyoct-1-enyl]-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-2-ylidene]pentanoic acid
(5Z,13E,15S)-6,9alpha-epoxy-11alpha,15-dihydroxyprosta-5,13-dienoic acid
(5Z,13E,8R,9S,11R,12R,15S)-6,9-Epoxy-11,15-dihydroxyprosta-5,13-dien-1-oic acid sodium salt
(5Z,13E)-(15S)-6,9alpha-Epoxy-11alpha,15-dihydroxyprosta-5,13-dienoate
(5Z,9|A,11|A,13E,15S)-6,9-epoxy-11,15-Dihydroxy-prosta-5,13-dien-1-oic Acid Sodium Salt
(5Z,9alpha,11alpha,13E,15S)-11,15-dihydroxy-6,9-epoxyprosta-5,13-dien-1-oic acid
(5Z,9alpha,11alpha,13E,15S)-6,9-epoxy-11,15-dihydroxyprosta-5,13-dien-1-oic acid
(5Z)-5-[(3aR,4R,5R,6aS)-5-hydroxy-4-[(E,3S)-3-hydroxyoct-1-enyl]-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-2-ylidene]pentanoic acid
(5Z)-5-[(3aR,4R,5R,6aS)-5-hydroxy-4-[(E,3S)-3-hydroxyoct-1-enyl]-3,3a,4,5,6,6a-hexahydrocyclopenta[d]furan-2-ylidene]pentanoic acid
(5Z)-5-[(4R,5R)-5-hydroxy-4-[(E,3S)-3-hydroxyoct-1-enyl]-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-2-ylidene]pentanoic acid
(Z)-(3aR,4R,5R,6aS)-Hexahydro-5-hydroxy-4-((E)-(3S)-3-hydroxy-1-octenyl)-2H-cyclopenta(b)furan-delta(sup 2,delta)-valeric acid
(Z)-5-((3aR,4R,5R,6aS)-5-hydroxy-4-((S,E)-3-hydroxyoct-1-en-1-yl)hexahydro-2H-cyclopenta[b]furan-2-ylidene)pentanoic acid
35121-78-9
4K04IQ1OF4
4UA76
5-[(3aR,4R,5R,6aS)-5-hydroxy-4-[(3S)-3-hydroxyoct-1-enyl]-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-2-ylidene]pentanoic acid
54231-EP2305653A1
54231-EP2308562A2
6,9-alpha-Epoxy-11-alpha,15(S)-dihydroxyprosta-5(Z),13(E)-dien-1-oic acid
6,9.alpha.-Epoxy-11.alpha.,15S-dihydroxyprosta-5Z,13E-dien-1-oic acid, monosodium salt
6,9S-epoxy-11R,15S-dihydoxy-5Z,13E-prostadienoic acid
61849-14-7
63748-50-5
63859-31-4
8222AH
88471-EP2272832A1
88471-EP2289518A1
88471-EP2292231A1
88471-EP2305260A1
88471-EP2305653A1
AC1NR00P
AC1O4BXH
AKOS024457370
BIDD:GT0514
BML1-F10
BRD-K64054020-001-02-7
BRN 1690090
BSPBio_001496
C20H31NaO5
C20H31O5.Na
CAS-61849-14-7
CHEBI:15552
CHEMBL1139
CHEMBL962
Cyclo-Prostin
D0V0IX
DCR9Z582X0
DSSTox_CID_26617
DSSTox_GSID_46617
DSSTox_RID_81769
DTXSID3046617
DTXSID5022988
EINECS 263-273-7
Epoprostanol
epoprostenol
Epoprostenol (USAN/INN)
Epoprostenol [USAN:INN]
Epoprostenol sodium [USAN:BAN]
Epoprostenol Sodium Salt, (5Z,9alpha,11alpha,13E,15S)-Isomer
Epoprostenolsodium
Epoprostenolum
Epoprostenolum [INN-Latin]
Flolan
Floran
GTPL1915
HMS1361K18
HMS1791K18
HMS1989K18
HMS3402K18
HMS3648L14
IDI1_033966
KAQKFAOMNZTLHT-OZUDYXHBSA-N
KB-IV-24
LMFA03010087
LMHIPJMTZHDKEW-XQYLJSSYSA-M
LS-176206
MolPort-006-132-470
NCGC00161285-01
NCGC00161285-02
NCGC00161285-03
NCGC00167427-01
PG-I2
PGI(sub 2)
PGI2
PGX
Prosta-5,13-dien-1-oic acid, 6,9-epoxy-11,15-dihydroxy-, (5Z,9alpha,11alpha,13E,15S)-
Prosta-5,13-dien-1-oic acid, 6,9-epoxy-11,15-dihydroxy-, sodium salt, (5Z,9alpha,11alpha,13E,15S)-
prostacyclin
Prostacyclin I2
Prostacyclin sodium
Prostacyclin sodium salt
Prostacycline
Prostacyclins
Prostaglandin 12
Prostaglandin I(2)
prostaglandin I2
PROSTAGLANDIN I2 Na
Prostaglandin I2 sodium
Prostaglandin X
Prostaglandin X sodium
ProstaglandinI
Prostaglandins X
SCHEMBL41344
SCHEMBL8041
SMP2_000227
Sodium (5Z,13E,15S)-6,9alpha-epoxy-11alpha,15-dihydroxyprosta-5,13-dien-1-oate
sodium (5Z)-5-[(3aR,4R,5R,6aS)-5-hydroxy-4-[(E,3S)-3-hydroxyoct-1-enyl]-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-2-ylidene]pentanoate
Sodium (Z)-(3aR,4R,5R,6aS)-hexahydro-5-hydroxy-4-((E)-(3S)-3-hydroxy-1-octenyl)-2H-cyclopenta(b)furan-delta(sup 2,delta)-valerate
Tox21_112431
TRY 200
Try-200
U 53,217
U 53,217A
U-53,217
U-53217
U-53217A
UNII-4K04IQ1OF4
UNII-DCR9Z582X0
V0155
Vasocyclin
ZINC3813078

US Patents and Regulatory Information for epoprostenol sodium

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Actelion Pharms Ltd VELETRI epoprostenol sodium INJECTABLE;INJECTION 022260-001 Jun 27, 2008 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Teva Pharms Usa EPOPROSTENOL SODIUM epoprostenol sodium INJECTABLE;INJECTION 078396-001 Apr 23, 2008 AP RX No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Glaxosmithkline Llc FLOLAN epoprostenol sodium INJECTABLE;INJECTION 020444-002 Sep 20, 1995 AP RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Actelion Pharms Ltd VELETRI epoprostenol sodium INJECTABLE;INJECTION 022260-002 Jun 28, 2012 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Glaxosmithkline Llc FLOLAN epoprostenol sodium INJECTABLE;INJECTION 020444-001 Sep 20, 1995 AP RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Expired US Patents for epoprostenol sodium

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Glaxosmithkline Llc FLOLAN epoprostenol sodium INJECTABLE;INJECTION 020444-002 Sep 20, 1995 ➤ Try a Free Trial ➤ Try a Free Trial
Glaxosmithkline Llc FLOLAN epoprostenol sodium INJECTABLE;INJECTION 020444-001 Sep 20, 1995 ➤ Try a Free Trial ➤ Try a Free Trial
Glaxosmithkline Llc FLOLAN epoprostenol sodium INJECTABLE;INJECTION 020444-002 Sep 20, 1995 ➤ Try a Free Trial ➤ Try a Free Trial
Glaxosmithkline Llc FLOLAN epoprostenol sodium INJECTABLE;INJECTION 020444-001 Sep 20, 1995 ➤ Try a Free Trial ➤ Try a Free Trial
Glaxosmithkline Llc FLOLAN epoprostenol sodium INJECTABLE;INJECTION 020444-001 Sep 20, 1995 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
Express Scripts
Cantor Fitzgerald
Colorcon
Moodys
QuintilesIMS
McKinsey
Dow
Healthtrust

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.